NO20033145L - Purinderivater som purinergiske reseptorantagonister - Google Patents
Purinderivater som purinergiske reseptorantagonisterInfo
- Publication number
- NO20033145L NO20033145L NO20033145A NO20033145A NO20033145L NO 20033145 L NO20033145 L NO 20033145L NO 20033145 A NO20033145 A NO 20033145A NO 20033145 A NO20033145 A NO 20033145A NO 20033145 L NO20033145 L NO 20033145L
- Authority
- NO
- Norway
- Prior art keywords
- sub
- alkyl
- aryl
- conr
- disorder
- Prior art date
Links
- 229940083251 peripheral vasodilators purine derivative Drugs 0.000 title 1
- 239000000111 purinergic antagonist Substances 0.000 title 1
- 229940121374 purinergic receptor antagonist Drugs 0.000 title 1
- 125000000561 purinyl group Chemical class N1=C(N=C2N=CNC2=C1)* 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 6
- 125000003118 aryl group Chemical group 0.000 abstract 5
- 150000001875 compounds Chemical class 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 208000035475 disorder Diseases 0.000 abstract 3
- 125000001072 heteroaryl group Chemical group 0.000 abstract 3
- 125000000623 heterocyclic group Chemical group 0.000 abstract 3
- 208000002193 Pain Diseases 0.000 abstract 2
- -1 0thioalkyl Chemical group 0.000 abstract 1
- 102000009346 Adenosine receptors Human genes 0.000 abstract 1
- 108050000203 Adenosine receptors Proteins 0.000 abstract 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 abstract 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 abstract 1
- 208000000094 Chronic Pain Diseases 0.000 abstract 1
- 208000028698 Cognitive impairment Diseases 0.000 abstract 1
- 208000016285 Movement disease Diseases 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 102000000033 Purinergic Receptors Human genes 0.000 abstract 1
- 108010080192 Purinergic Receptors Proteins 0.000 abstract 1
- 230000001154 acute effect Effects 0.000 abstract 1
- 208000005298 acute pain Diseases 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000004104 aryloxy group Chemical group 0.000 abstract 1
- 230000009286 beneficial effect Effects 0.000 abstract 1
- 230000000903 blocking effect Effects 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 208000010877 cognitive disease Diseases 0.000 abstract 1
- 230000001149 cognitive effect Effects 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 206010027175 memory impairment Diseases 0.000 abstract 1
- 201000003631 narcolepsy Diseases 0.000 abstract 1
- 230000004112 neuroprotection Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- 125000005000 thioaryl group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/28—Oxygen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/36—Sulfur atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/40—Heterocyclic compounds containing purine ring systems with halogen atoms or perhalogeno-alkyl radicals directly attached in position 2 or 6
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0100623.8A GB0100623D0 (en) | 2001-01-10 | 2001-01-10 | Chemical compounds IV |
| PCT/GB2002/000076 WO2002055521A1 (en) | 2001-01-10 | 2002-01-10 | Purine derivatives as purinergic receptor antagonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO20033145D0 NO20033145D0 (no) | 2003-07-09 |
| NO20033145L true NO20033145L (no) | 2003-09-09 |
Family
ID=9906570
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20033145A NO20033145L (no) | 2001-01-10 | 2003-07-09 | Purinderivater som purinergiske reseptorantagonister |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US7452894B2 (de) |
| EP (1) | EP1349857B1 (de) |
| JP (1) | JP4284069B2 (de) |
| KR (1) | KR20030079945A (de) |
| CN (1) | CN1617871A (de) |
| AT (1) | ATE471323T1 (de) |
| AU (1) | AU2002217331B2 (de) |
| BR (1) | BR0206561A (de) |
| CA (1) | CA2433858C (de) |
| CZ (1) | CZ20031956A3 (de) |
| DE (1) | DE60236719D1 (de) |
| GB (1) | GB0100623D0 (de) |
| HU (1) | HUP0402504A2 (de) |
| IL (1) | IL156779A0 (de) |
| MX (1) | MXPA03006163A (de) |
| NO (1) | NO20033145L (de) |
| NZ (1) | NZ527249A (de) |
| PL (1) | PL363172A1 (de) |
| RU (1) | RU2003124653A (de) |
| WO (1) | WO2002055521A1 (de) |
| YU (1) | YU55603A (de) |
| ZA (1) | ZA200305116B (de) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE60220658T2 (de) * | 2001-04-05 | 2008-02-21 | Sumitomo Chemical Co., Ltd. | Verfahren zur produktion von 2,6-dihalogenopurinen |
| WO2003037860A2 (en) | 2001-10-30 | 2003-05-08 | Conforma Therapeutics Corporation | Purine analogs having hsp90-inhibiting activity |
| US7414036B2 (en) | 2002-01-25 | 2008-08-19 | Muscagen Limited | Compounds useful as A3 adenosine receptor agonists |
| DE10252650A1 (de) * | 2002-11-11 | 2004-05-27 | Grünenthal GmbH | Cyclohexyl-Harnstoff-Derivate |
| MXPA06002997A (es) * | 2003-09-18 | 2007-02-08 | Conforma Therapeutics Corp | Novedosos compuestos heterociclicos como inhibidores- hsp90. |
| JPWO2005085210A1 (ja) * | 2004-03-10 | 2008-01-17 | 小野薬品工業株式会社 | ニトリル化合物およびその化合物を有効成分として含有する医薬組成物 |
| MY140748A (en) | 2004-12-06 | 2010-01-15 | Astrazeneca Ab | Novel pyrrolo [3,2-d] pyrimidin-4-one derivatives and their use in therapy |
| AU2006230447A1 (en) | 2005-03-30 | 2006-10-05 | Conforma Therapeutics Corporation | Alkynyl pyrrolopyrimidines and related analogs as HSP90-inhibitors |
| US20090023723A1 (en) * | 2005-09-21 | 2009-01-22 | Pharmacopeia Drug Discovery, Inc. | Purinone derivatives for treating neurodegenerative diseases |
| CN1947717B (zh) * | 2005-10-14 | 2012-09-26 | 卓敏 | 选择性抑制腺苷酸环化酶1的化合物在制备用于治疗神经性疼痛和炎性疼痛的药物中的应用 |
| US7989459B2 (en) | 2006-02-17 | 2011-08-02 | Pharmacopeia, Llc | Purinones and 1H-imidazopyridinones as PKC-theta inhibitors |
| TW200837064A (en) | 2006-10-04 | 2008-09-16 | Pharmacopeia Inc | 8-substituted 2-(benzimidazolyl)purine derivatives for immunosuppression |
| US7919490B2 (en) | 2006-10-04 | 2011-04-05 | Wyeth Llc | 6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression |
| US7902187B2 (en) | 2006-10-04 | 2011-03-08 | Wyeth Llc | 6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression |
| US20090054468A1 (en) * | 2007-08-23 | 2009-02-26 | Astrazeneca Ab | New Use 938 |
| EP2209786B1 (de) | 2007-10-05 | 2013-02-27 | Verastem, Inc. | Pyrimidinsubstituierte purinderivate |
| GB0906579D0 (en) * | 2009-04-16 | 2009-05-20 | Vernalis R&D Ltd | Pharmaceuticals, compositions and methods of making and using the same |
| WO2010114484A1 (en) | 2009-04-03 | 2010-10-07 | S*Bio Pte Ltd | Pyrimidine substituted purine compounds as kinase (s) inhibitors |
| PL3446714T3 (pl) | 2011-06-02 | 2021-11-22 | University Of Louisville Research Foundation, Inc. | Nanocząstki sprzężone z cząsteczką skierowaną przeciwko nukleolinie |
| WO2012172043A1 (en) * | 2011-06-15 | 2012-12-20 | Laboratoire Biodim | Purine derivatives and their use as pharmaceuticals for prevention or treatment of bacterial infections |
| EP2840083B1 (de) * | 2012-04-17 | 2017-09-13 | Astellas Pharma Inc. | Nitrogenierte bicyclische aromatische heterocyclische verbindung |
| JP7098633B2 (ja) * | 2016-11-18 | 2022-07-11 | ザ プロクター アンド ギャンブル カンパニー | 効果を提供するための布地処理組成物及び方法 |
| US10870816B2 (en) | 2016-11-18 | 2020-12-22 | The Procter & Gamble Company | Fabric treatment compositions having low calculated cationic charge density polymers and fabric softening actives and methods for providing a benefit |
| WO2019039438A1 (ja) * | 2017-08-21 | 2019-02-28 | 国立大学法人三重大学 | 非ヒト哺乳類の脳梗塞モデルによる観察方法及び非ヒト哺乳類の脳梗塞モデルによる観察装置 |
| CN107903274A (zh) * | 2017-12-28 | 2018-04-13 | 窦玉玲 | 一种胺类化合物及其在抗肿瘤药物中的应用 |
| EP3993793A4 (de) * | 2019-07-01 | 2023-06-28 | Ligang Qian | P2x7r-antagonisten |
| KR20210061202A (ko) * | 2019-11-19 | 2021-05-27 | 일동제약(주) | 벤조나이트릴이 치환된 축합 피리미딘 유도체 및 그의 의약 용도 |
| US11787775B2 (en) * | 2020-07-24 | 2023-10-17 | Genentech, Inc. | Therapeutic compounds and methods of use |
| US11806350B2 (en) | 2020-11-19 | 2023-11-07 | Ildong Pharmaceutical Co., Ltd. | Prevention and/or treatment of CNS disorders |
| CN116589464B (zh) * | 2022-02-14 | 2025-10-31 | 上海科技大学 | 嘧啶并环类化合物、其制备方法和应用 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3630997A (en) * | 1970-05-04 | 1971-12-28 | Paul M Craven | Curable epoxy resin compositions and method of preparing same |
| US5064745A (en) * | 1988-02-25 | 1991-11-12 | Mitsubishi Paper Mills, Ltd. | Method for making lithographic printing plate |
| US5403932A (en) * | 1988-05-25 | 1995-04-04 | Research Corporation Technologies, Inc. | Phosphoramidates useful as antitumor agents |
| US5968989A (en) * | 1991-12-18 | 1999-10-19 | The Salk Institute For Biological Studies | Means for the modulation of processes mediated by retinoid receptors and compounds useful therefor |
| IL108523A0 (en) * | 1993-02-03 | 1994-05-30 | Gensia Inc | Pharmaceutical compositions containing adenosine kinase inhibitors for preventing or treating conditions involving inflammatory responses and pain |
| DE4330735A1 (de) * | 1993-09-10 | 1995-03-16 | Wacker Chemie Gmbh | Hydrophile Gruppen aufweisende Organopolysiloxane |
| US5789416B1 (en) * | 1996-08-27 | 1999-10-05 | Cv Therapeutics Inc | N6 mono heterocyclic substituted adenosine derivatives |
| PL337888A1 (en) | 1997-07-03 | 2000-09-11 | Du Pont Pharm Co | Imidazoprimidines and imidazopyridines for use in treating neurological disorders |
| EP0975345A1 (de) | 1997-11-26 | 2000-02-02 | Cerebrus Pharmaceuticals Limited | (-)-mefloquine zur blockierung der purinrezeptoren und zur behandlung von bewegung- oder neurodegenerativen erkrankungen |
| AU1688599A (en) | 1998-01-05 | 1999-07-26 | Eisai Co. Ltd. | Purine derivatives and adenosine a2 receptor antagonists serving as preventives/remedies for diabetes |
| JPH11279193A (ja) | 1998-03-24 | 1999-10-12 | Akira Matsuda | アデノシン誘導体 |
| GB9819382D0 (en) | 1998-09-04 | 1998-10-28 | Cerebrus Ltd | Chemical compounds I |
| GB9819384D0 (en) | 1998-09-04 | 1998-10-28 | Cerebrus Ltd | Chemical compounds II |
| GB9915437D0 (en) | 1999-07-01 | 1999-09-01 | Cerebrus Ltd | Chemical compounds III |
| US6841549B1 (en) | 1999-07-02 | 2005-01-11 | Eisai Co., Ltd. | Condensed imidazole compounds and a therapeutic agent for diabetes mellitus |
| MXPA02009659A (es) * | 2000-04-26 | 2003-03-10 | Warner Lambert Co | Derivado de ciclohexilamina como subtipo de los antagonistas del receptor selectivo nmda. |
| US6903238B2 (en) * | 2001-12-13 | 2005-06-07 | Wyeth | Substituted indenones as estrogenic agents |
| US6946005B2 (en) * | 2002-03-27 | 2005-09-20 | L'oreal S.A. | Pyrrolidinyl-substituted para-phenylenediamine derivatives substituted with a cationic radical, and use of these derivatives for dyeing keratin fibers |
| DE10326303A1 (de) * | 2003-06-11 | 2004-12-30 | Celares Gmbh | Reagenzien zur Modifikation von Biopharmazeutika, deren Herstellung und Anwendung |
| CN101103026A (zh) * | 2005-01-14 | 2008-01-09 | 健亚生物科技公司 | 用于治疗病毒感染的吲哚衍生物 |
| EP1934243B1 (de) * | 2005-09-09 | 2011-05-25 | Boehringer Ingelheim International GmbH | Cyclisierendes metatheseverfahren zur herstellung von makrocyclischen peptiden |
| ATE450262T1 (de) * | 2005-11-25 | 2009-12-15 | Galapagos Sas | Harnstoff-derivate als calcium-rezeptor- modulatoren |
| US8143236B2 (en) * | 2005-12-13 | 2012-03-27 | Bionumerik Pharmaceuticals, Inc. | Chemoprotective methods |
| BRPI0714299A2 (pt) * | 2006-07-20 | 2013-04-24 | Genelabs Tech Inc | inibidores virais policÍclicos |
-
2001
- 2001-01-10 GB GBGB0100623.8A patent/GB0100623D0/en not_active Ceased
-
2002
- 2002-01-10 DE DE60236719T patent/DE60236719D1/de not_active Expired - Lifetime
- 2002-01-10 MX MXPA03006163A patent/MXPA03006163A/es unknown
- 2002-01-10 NZ NZ527249A patent/NZ527249A/xx unknown
- 2002-01-10 CZ CZ20031956A patent/CZ20031956A3/cs unknown
- 2002-01-10 IL IL15677902A patent/IL156779A0/xx unknown
- 2002-01-10 AT AT02729444T patent/ATE471323T1/de not_active IP Right Cessation
- 2002-01-10 YU YU55603A patent/YU55603A/sh unknown
- 2002-01-10 BR BR0206561-4A patent/BR0206561A/pt not_active Application Discontinuation
- 2002-01-10 JP JP2002556190A patent/JP4284069B2/ja not_active Expired - Fee Related
- 2002-01-10 CA CA2433858A patent/CA2433858C/en not_active Expired - Fee Related
- 2002-01-10 RU RU2003124653/04A patent/RU2003124653A/ru not_active Application Discontinuation
- 2002-01-10 PL PL02363172A patent/PL363172A1/xx not_active Application Discontinuation
- 2002-01-10 AU AU2002217331A patent/AU2002217331B2/en not_active Ceased
- 2002-01-10 US US10/250,941 patent/US7452894B2/en not_active Expired - Fee Related
- 2002-01-10 EP EP02729444A patent/EP1349857B1/de not_active Expired - Lifetime
- 2002-01-10 HU HU0402504A patent/HUP0402504A2/hu unknown
- 2002-01-10 WO PCT/GB2002/000076 patent/WO2002055521A1/en not_active Ceased
- 2002-01-10 CN CNA028062582A patent/CN1617871A/zh active Pending
- 2002-01-10 KR KR10-2003-7009241A patent/KR20030079945A/ko not_active Withdrawn
-
2003
- 2003-07-01 ZA ZA200305116A patent/ZA200305116B/xx unknown
- 2003-07-09 NO NO20033145A patent/NO20033145L/no not_active Application Discontinuation
-
2006
- 2006-07-19 US US11/488,750 patent/US20060270691A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| NZ527249A (en) | 2005-04-29 |
| RU2003124653A (ru) | 2005-01-10 |
| CN1617871A (zh) | 2005-05-18 |
| ATE471323T1 (de) | 2010-07-15 |
| PL363172A1 (en) | 2004-11-15 |
| WO2002055521A1 (en) | 2002-07-18 |
| JP2004517874A (ja) | 2004-06-17 |
| EP1349857A1 (de) | 2003-10-08 |
| CA2433858C (en) | 2010-12-14 |
| NO20033145D0 (no) | 2003-07-09 |
| IL156779A0 (en) | 2004-02-08 |
| MXPA03006163A (es) | 2003-09-16 |
| US20040102459A1 (en) | 2004-05-27 |
| CZ20031956A3 (cs) | 2003-11-12 |
| US20060270691A1 (en) | 2006-11-30 |
| HUP0402504A2 (hu) | 2005-04-28 |
| CA2433858A1 (en) | 2002-07-18 |
| GB0100623D0 (en) | 2001-02-21 |
| DE60236719D1 (de) | 2010-07-29 |
| AU2002217331B2 (en) | 2006-06-29 |
| YU55603A (sh) | 2006-05-25 |
| BR0206561A (pt) | 2004-06-22 |
| EP1349857B1 (de) | 2010-06-16 |
| US7452894B2 (en) | 2008-11-18 |
| KR20030079945A (ko) | 2003-10-10 |
| ZA200305116B (en) | 2004-07-01 |
| JP4284069B2 (ja) | 2009-06-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20033145L (no) | Purinderivater som purinergiske reseptorantagonister | |
| DK1392312T3 (da) | Triazolo-4,5 d-pyrimidinderivater og anvendelse deraf som purinerge receptorantagonister | |
| DE60228817D1 (de) | THIENO(3,2-d)PYRIMIDINE UND FURANO(3,2-d)PYRIMIDINE UND DEREN VERWENDUNG ALS ANTAGONISTEN AN PURINERGEN REZEPTOREN | |
| DK1412354T3 (da) | Derivater af triazolylimidazopyridin og af triazolylpurinerne, der er egnede som ligander for adenosin A2a?-receptoren og deres anvendelse som medikamenter | |
| GEP20094723B (en) | Tetraazabenzo [e] azulene derivatives and analogs thereof | |
| EA200601160A1 (ru) | 2,6-бисгетероарил-4-аминопиримидины в качестве антагонистов аденозиновых рецепторов | |
| BRPI0510365A (pt) | composto, método de produção de um composto, antagonista do receptor nk2, pró-droga, agente farmacêutico, métodos para antagonizar um recpetor nk2 e para evitar ou tratar doenças gastrintestinais funcionais, e, uso do composto ou uma pró-droga do mesmo | |
| WO2003106428A8 (fr) | Derives d'arylsulfonamides et leur utilisation en tant que antagonistes au recepteur b1 de la bradykinine | |
| DE60228414D1 (de) | Pyrrolo 2,3-d pyrimidine und deren verwendung als purinreceptor antagonisten | |
| TW200716528A (en) | Cyclopropanecarboxamide derivatives | |
| BRPI0409959A (pt) | uso de derivados de azetidinacarboxamida em terapia | |
| CY1110145T1 (el) | Αλκυλο-υποκατεστημενες ινδολοκινοξαλινες | |
| DE60014394D1 (de) | Aminobenzophenone als inhibitoren von il-1beta und tnf-alpha | |
| HRP20080598T3 (en) | Combination of et-743 with 5-fluorouracil pro-drugs for the treatment of cancer | |
| FR2847899B1 (fr) | Derives d'indole-3-carboxamide, leur preparation et leur application en therapeutique | |
| BRPI0207102A8 (pt) | forma cristalina, composição farmacêutica, e, uso de uma forma cristalina. | |
| DE602004016328D1 (de) | 2-imidazo-benzothiazole als adenosin-rezeptor liganden | |
| WO2006029154A3 (en) | Novel compounds | |
| ATE238300T1 (de) | (3,4-dihydro-2h-benzo(1,4)oxazinyl-methyl)-3-(1 - indol-3-yl)-alkylamine | |
| TNSN07052A1 (fr) | Derives pyridiniques d'indolin-2-one, leur preparation et leur application en therapeutique | |
| MXPA04000615A (es) | Compuestos utiles para el tratamiento o la prevencion de enfermedades mediadas por alfa-2b-adrenoceptor. | |
| AR035699A1 (es) | Asociacion de al menos un derivado de piridoindolona, composicion farmaceutica que comprende al menos un derivado de piridoindolona y kit para el tratamiento de la proliferacion de celulas tumorales |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |